- Current report filing (8-K)
24 Oktober 2008 - 11:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: October 20, 2008
(Date
of earliest event reported)
Oragenics,
Inc
(Exact
name of registrant as specified in its charter)
FL
|
|
001-38122
|
|
59-3410522
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
Number)
|
|
|
|
13700
Progress Blvd
|
|
32615
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
386-418-4018
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
October 20, 2008, the Company obtained from Signature Bank of New York, New
York, a revolving line of credit in the amount of up to $1,000,000.00, for
the
purpose of providing working capital to the Company, which is secured by cash
collateral of the Company in the same amount deposited with Signature Bank,
bears interest at the Prime Rate of Signature Bank, as effective from time
to
time, and has a final maturity of October 20, 2009. Other than submission of
periodic financial information of the Company to Signature Bank, the loan
documentation evidencing the revolving line of credit does not contain any
financial covenants. In connection with the revolving line of credit, the
Company entered into a letter agreement, promissory note and pledge agreement
(collectively “the Credit Agreements”) with Signature Bank. The Company does not
currently expect to draw down any funds from the available Credit Agreement,
but
it wanted to have the availability to do so in the future in connection with
its
potential product manufacturing needs.
A
copy of
the Credit Agreements are attached to this report as Exhibit 10.1 and are
incorporated herein by reference.
Item
9.01
FINANCIAL
INFORMATION AND EXHIBITS
(c)
Exhibits.
Number
|
Description
|
10.1
|
Letter
Agreement; Promissory Note; and Pledge Agreement between Oragenics,
Inc.
and Signature Bank dated October 20,
2008
|
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused
this
report to be signed on its behalf by the undersigned, thereunto duly authorized
on this 24
th
day of
October, 2008.
|
|
|
|
ORAGENICS,
INC.
|
|
|
|
|
BY:
|
/s/David
B. Hirsch
|
|
David
B. Hirsch
|
|
Chief
Financial Officer
|
Oragenics (AMEX:ONI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Oragenics (AMEX:ONI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024